Risk of meningioma with cyproterone acetate
- PDF / 169,210 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 11 Downloads / 172 Views
1
Risk of meningioma with cyproterone acetate A recent issue of Prescriber Update reminds healthcare professionals of the risk of single or multiple meningiomas in patients receiving cyproterone acetate. The synthetic progestogen with anti-androgenic activity is indicated as an antiandrogen treatment in men or for severe signs of androgenisation in women. A recent French cohort study demonstrated a dose-dependent association between cyproterone acetate and the risk of meningioma. Meningioma occurrence primarily occurs at doses ≥25 mg/day. The New Zealand Centre for Adverse Reactions Monitoring (CARM) reports two cases of meningioma in women who had been treated for >10 years. Cyproterone acetate treatment must be permanently stopped if meningioma development occurs. Drug use is contraindicated in patients with a meningioma or a history of meningioma. New Zealand Medicines and Medical Devices Safety Authority. Cyproterone acetate and the risk of meningioma. Prescriber Update 41: 55-56, No. 3, Sep 2020. Available 803502317 from: URL: https://www.medsafe.govt.nz/profs/PUArticles/PDF/Prescriber-Update-vol-41-No-3-(Sep-2020).pdf
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
